

# The Endocrine Perspective on Managing the Diabetic Foot

Dr Ketan Dhatariya MSc MD MS FRCP

Consultant in Diabetes and Endocrinology Norfolk and Norwich University Hospitals

9th March 2012





# or, as I would like to call it.....

Dr Ketan Dhatariya MSc MD MS FRCP

Consultant in Diabetes and Endocrinology Norfolk and Norwich University Hospitals

9th March 2012





# What Surgeons Should Know Before Taking Someone with Diabetes to Theatre

Dr Ketan Dhatariya MSc MD MS FRCP

Consultant in Diabetes and Endocrinology Norfolk and Norwich University Hospitals

9th March 2012



#### Excess Mean Length of Stay in Diabetes Inpatients Aged 18 – 60 Years 269,265 Diabetes Discharges and 4,411,593 Matched Controls

|       | Mean LOS (days) |           | Excess LOS (days) |     |     | n      |        |           |
|-------|-----------------|-----------|-------------------|-----|-----|--------|--------|-----------|
|       | E10             | E11       | С                 | E10 | E11 | E10    | E11    | С         |
| Surg. | 5.4 (0.1)       | 5.1 (0.1) | 4.2 (0.2)         | 1.2 | 0.9 | 18,032 | 32,135 | 1,501,453 |
| T &O  | 4.8 (0.1)       | 5.3 (0.2) | 4.6 (0.1)         | 0.2 | 0.7 | 8,178  | 12,203 | 885,606   |
| GM    | 4.8 (0.2)       | 5.4 (0.2) | 4.4 (0.1)         | 0.4 | 1.0 | 70,988 | 82,446 | 1,709,553 |
| Card. | 4.2 (0.1)       | 4.2 (0.1) | 3.8 (0.1)         | 0.4 | 0.4 | 5,307  | 15,009 | 229,784   |
| MFE   | 4.8 (0.2)       | 5.6 (0.2) | 4.7 (0.1)         | 0.1 | 0.1 | 2,444  | 4,549  | 85,197    |
|       |                 | - 4 11    |                   |     | _ ^ |        |        |           |

E10 = Type 1 diabetes E11 = Type 2 diabetes c = controls

English Hospitals, 4 consecutive years of discharges 2000-2004

Sampson MJ et al Diabetes Research & Clinical Practice 2007;77(1):92-98




# Do Peri-Operative High Glucose Levels Cause Harm?

- High pre-operative glucose or HbA1c has been related to adverse outcomes following
  - spinal surgery
  - vascular surgery
  - colorectal surgery
  - cardiac surgery
  - trauma




# Do High Admission Glucose Levels Cause Harm?



- Patients with diabetes
- Patients without diabetes




# Do High Admission Glucose Levels Cause Harm?



- Patients with diabetes
- A Patients without diabetes




## Do High Glucose Levels Cause Harm?





#### An Admission



- Patients with diabetes
- Patients without diabetes



#### Thus....

- Whilst there is data to show that poor glycaemic control is associated with poor outcomes
- There is no consistent data to show that improving control also improves outcomes

(A bit like diabetes care in general until the mid 1990's)



#### A Little Bit of Local Data From Medicine



# So, Is Admission Hyperglycaemia Important?

- We analysed the data for all 1,502 patients admitted through our AMU in February 2010
- We assessed
  - admission blood glucose,
  - LOS
  - 28-days readmission and mortality
  - whether admission blood glucose ≥11.1mmol/l in non-diabetic individuals was followed-up




#### Who Admitted Them?

| Specialty                | Number of patients | Number with diabetes |  |
|--------------------------|--------------------|----------------------|--|
| Medicine for the elderly | 577                | 94 (16.3%)           |  |
| Cardiology               | 221                | 25 (11.3%)           |  |
| Respiratory              | 200                | 28 (14%)             |  |
| Nephrology               | 30                 | 9 (30%)              |  |
| Gastroenterology         | 132                | 18 (13.6%)           |  |
| Endocrinology            | 30                 | 22 (73%)             |  |
| Neurology                | 77                 | 12 (16.9%)           |  |
| Dermatology              | 1                  | 0 (0%)               |  |
| Haematology              | 16                 | 0 (0%)               |  |
| Oncology                 | 56                 | 4 (7.4%)             |  |
| General medicine         | 162                | 27 (16.7%)           |  |




### LOS vs Admission Glucose



Evans N, Dhatariya K Clinical Medicine 2012 In Press



# 28 Day Readmission vs Admission Glucose




Blood glucose (mmol/L)

Evans N, Dhatariya K Clinical Medicine 2012 In Press



## 28 Day Mortality vs Admission Glucose



Evans N, Dhatariya K Clinical Medicine 2012 In Press



## Follow up

- 37 (2.5%) of the total number of admissions were individuals without an existing diagnosis of diabetes who had an admission blood glucose of ≥ 11.1mmol/l
- Of these, only 19 (51.4%) received further follow-up at 28 days



# What About Local Surgical Data?

- I have just got a junior to start collecting this data prospectively for 3 months on the EAU(S)
- Watch this space......
- In the meantime, we have audit




# The Care of Patients with Diabetes Undergoing Arthroplasty

Annemarie Brunswicker
Mr Alan Howieson
Dr Ketan Dhatariya



# They Took the Audit Tools in This





#### The Patients

- 50 consecutive arthoplasty patients with diabetes between July 2010 and June 2011
- Admitted through pre-assessment clinic



### Institutional Standards

- Are the national guidelines adopted? Yes
- Does the trust collect diabetic outcome data for surgical patients?
- Does the trust have dedicated diabetic nurses?
   Yes
- Does the trust have a clinical lead for perioperative care for people with diabetes?

### More Standards

- Primary care referrals contain all suggested information: 100%
- Patients pre-operatively assessed: 100%
- Patients with diabetes management plan: 100%
- Admitted on day of surgery: 90%
- Listed 1<sup>st</sup> on list: 95%
- Length of stay: no longer than 10% greater than average

### And More.....

- Patients receive hourly blood glucose monitoring: 100%
- Patients blood glucose maintained between 4-12mmol/l: 100%
- Patients with delayed discharge due to diabetes:
   0%



# GP Referral Letters Adequate?

48%

| • HbA1 <sub>C</sub>             | 0%  |
|---------------------------------|-----|
| • BP                            | 16% |
| • PMH                           | 84% |
| <ul> <li>Medications</li> </ul> | 84% |
| • BMI                           | 20% |
| • eGFR                          | 4%  |
|                                 |     |

Duration of diabetes



# And So On.....



# **Overall Summary**

- Primary care referrals with all suggested information: not achieved
- Patients pre-operatively assessed: achieved
- Patients with diabetes management plan: not achieved
- Admitted on day of surgery: achieved
- Listed 1<sup>st</sup> on list: not achieved
- Length of stay: no longer than 10% greater than average: achieved for TKR

# OK, So What is in Your Control?

- Ask the GP's for standardised referral letters containing the following information
  - Duration and type of diabetes
  - Place of usual diabetes care (primary or secondary)
  - Other co-morbidities
  - Treatment
    - for diabetes oral agents/ insulin doses and frequency
    - For other co-morbidities
  - Complications
    - At risk foot
  - Renal impairment
  - Cardiac disease
  - Relevant measures
  - BMI
  - BP
  - HbA1c
  - eGFR



### What Else Can You Influence?

- That pre-operative assessment clinic staff are educated in diabetes management
- That the way to manipulate the drugs prior to surgery is easily available and individualised for all patients
- That patients are listed as close to the beginning of the list as possible - to minimise starvation times

| Tablets   | Day prior to   | Day of surgery                            |   |  |  |
|---|----------------|---|---|--|--|
|   | admission      | Patient for<br>AM surgery                 | Patient for<br>PM surgery                           |  |  |
| Acarbose  | Take as normal | Omit morning dose<br>if NBM               | Give morning dose if eating                         |  |  |
| <b>Meglitinide</b><br>(repaglinide or<br>nateglinide)                       | Take as normal | Omit morning dose if<br>NBM               | Give morning dose if eating                         |  |  |
| Metformin<br>(procedure not requiring<br>use of contrast media*)            | Take as normal | Take as normal                            | Take as normal                                      |  |  |
| Sulphonylurea<br>(e.g Glibenclamide,<br>Gliclazide, Glipizide, etc.)        | Take as normal | Once daily AM omit<br>Twice daily omit AM | Once daily AM omit<br>Twice daily omit<br>AM and PM |  |  |
| Pioglitazone  | Take as normal | Take as normal                            | Take as normal                                      |  |  |
| <b>DPP IV inhibitor</b><br>(e.g. Sitagliptin,<br>Vildagliptin, Saxagliptin) | Take as normal | Omit on day of surgery                    | Omit on day of surgery                              |  |  |
| <b>GLP-1 analogue</b><br>(e.g. Exenatide,<br>Liraglutide)                   | Take as normal | Omit on day of surgery                    | Omit on day of surgery                              |  |  |

| Insulins   | Day prior to    | Day of surgery  |  |  |  |
|--|-----------------|---|--|--|--|
|  | admission       | Patient for<br>AM surgery   | Patient for<br>PM surgery  |  |  |
| Once daily (evening)<br>(e.g. Lantus® or Levemir®.<br>Insulatard®, Humulin I®,<br>Insuman®)  | No dose change* | Check blood glucose<br>on admission   | Check blood glucose<br>on admission  |  |  |
| Once daily (morning)<br>(Lantus® or Levemir®<br>Insulatard®, Humulin I®,<br>Insuman®)  | No dose change  | No dose change*.<br>Check blood glucose<br>on admission   | No dose change*.<br>Check blood glucose<br>on admission  |  |  |
| Twice daily (e.g. Novomix 30®, Humulin M3® Humalog Mix 25®, Humalog Mix 50®, Insuman® Comb 25, Insuman® Comb 50 twice daily Levemir® or Lantus®)                                     | No dose change  | Halve the usual morning<br>dose. Check blood<br>glucose on admission.<br>Leave the evening meal<br>dose unchanged   | Halve the usual morning<br>dose. Check blood<br>glucose on admission.<br>Leave the evening meal<br>dose unchanged  |  |  |
| Twice daily - separate injections of short acting (e.g. animal neutral, Novorapid® Humulin S®) Apidra® and intermediate acting (e.g. animal isophane Insulatard® HumulinI® Insuman®) | No dose change  | Calculate the total dose of both morning insulins and give half as intermediate acting only in the morning. Check blood glucose on admission.  Leave the evening meal dose unchanged                        | Calculate the total dose of both morning insulins and give half as intermediate acting only in the morning. Check blood glucose on admission.  Leave the evening meal dose unchanged |  |  |
| 3, 4, or 5 injections<br>daily   | No dose change  | Basal bolus regimens: omit the morning and lunchtime short acting insulins. Keep the basal unchanged.* Premixed AM insulin: halve the morning dose and omit lunchtime dose Check blood glucose on admission | Take usual morning<br>insulin dose(s). Omit<br>lunchtime dose. Check<br>blood glucose on<br>admission  |  |  |




#### The Future

- If acute admission hyperglycaemia is associated with poor outcomes in medical and surgical patients, then does lowering glucose on admission make a difference?
- Intervention Trials!



#### In The Meantime - It's a Minefield

 Remember, if you knew that without you even TOUCHING the patient you could <u>potentially</u> reduce their peri-operative mortality by 40 fold would you do that first?



Thank you for your attention



# What Surgeons Should Know Before Taking Someone with Diabetes to Theatre

Dr Ketan Dhatariya MSc MD MS FRCP

Consultant in Diabetes and Endocrinology Norfolk and Norwich University Hospitals

www.norfolkdiabetes.com

